PhaseBio Pharmaceuticals Valuation
Is PHAS undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score 1/6
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Key Valuation Metric
Which metric is best to use when looking at relative valuation for PHAS?
Other financial metrics that can be useful for relative valuation.
|What is PHAS's n/a Ratio?|
Price to Sales Ratio vs Peers
How does PHAS's PS Ratio compare to its peers?
|PHAS PS Ratio vs Peers|
|Company||PS||Estimated Growth||Market Cap|
LOGC LogicBio Therapeutics
XBIO Xenetic Biosciences
APVO Aptevo Therapeutics
PHAS PhaseBio Pharmaceuticals
Price-To-Sales vs Peers: PHAS is expensive based on its Price-To-Sales Ratio (10.7x) compared to the peer average (7.8x).
Price to Earnings Ratio vs Industry
How does PHAS's PE Ratio compare vs other companies in the US Biotechs Industry?
Price-To-Sales vs Industry: PHAS is good value based on its Price-To-Sales Ratio (10.7x) compared to the US Biotechs industry average (13.2x)
Price to Sales Ratio vs Fair Ratio
What is PHAS's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
|Current PS Ratio||10.7x|
|Fair PS Ratio||0x|
Price-To-Sales vs Fair Ratio: Insufficient data to calculate PHAS's Price-To-Sales Fair Ratio for valuation analysis.
Share Price vs Fair Value
What is the Fair Price of PHAS when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate PHAS's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate PHAS's fair value for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Target price is more than 20% higher than the current share price, but there are not enough analysts covering the stock to determine statistical confidence in agreement.
Discover undervalued companies
- Take a look at our analysis of PHAS's management and see if the CEO's compensation is within a reasonable range, who is on the board and if insiders have been trading lately.